Review· 2012
Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications.
Expert opinion on biological therapy
Related molecule only: full-length thymosin beta-4, not a TB-500 fragment trial.
Back to all molecules
PreclinicalNot FDA-approved
TB-500
Thymosin-beta-4-related fragment label
Also indexed as: Thymosin Beta-4 fragment
What this evidence does not tell us
The cited review concerns full-length thymosin beta-4. Its human research cannot be transferred to the TB-500 fragment; direct fragment evidence is limited.
Terms on this page
Unfamiliar word? Open this panel for simple explanations, right here.
6 glossary terms used in this profile
Terms on this page
Unfamiliar word? Open this panel for simple explanations, right here.
6 glossary terms used in this profile
Select a word to see its meaning. You can keep more than one definition open.
Definitions explain the words—not whether a molecule works or is safe. Research education only, not medical advice.
Overview
TB-500 is a label used for thymosin-beta-4-related research peptides, including the LKKTETQ fragment identified by FDA. It should not be assumed to mean full-length thymosin beta-4.
Mechanism of action
Actin / cell migration
A label used for thymosin-beta-4-related peptides, including the LKKTETQ fragment described by FDA. Full-length thymosin beta-4 participates in actin regulation; fragment activity and product identity require separate evidence.
A biological pathway describes a proposed or observed interaction—not necessarily a demonstrated health outcome.
Decode the terminology in our glossaryPut the research in context
Simplified educational maps—not a treatment pathway or a prediction of benefit.
Scientific evidence
How strong is the evidence?
Early lab & animal research
- Limited evidence
- Early researchCurrent category
- Human research
- Human outcomes
Most support comes from cells or animals. These studies help form questions, but do not prove a treatment works in people.
For this research: The cited review concerns full-length thymosin beta-4. Its human research cannot be transferred to the TB-500 fragment; direct fragment evidence is limited.
An editorial guide—not a validated score, a percentage, a safety rating or an approval badge. Regulatory status is separate. More research does not mean fewer risks.
Cell studies
Mechanistic laboratory evidence is not separately assessed in this selected-source summary; see references and their study types.
Animal experiments
Animal evidence is not separately assessed here. Findings in animals must not be interpreted as demonstrated human benefit.
Human observational studies
Associations, biomarker studies and anecdotes cannot establish treatment causality; no observational result is used here to infer clinical effectiveness.
Human clinical trials
Reliable, independently replicated human outcome evidence is not established by the selected sources in this edition.
Regulatory evidence
No FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval.
Potential research applications
Cell migration and tissue-repair hypotheses.
These describe scientific questions, not prescribing recommendations. A research grouping does not establish combination safety or clinical effectiveness.
Explore research by health goalSafety considerations
FDA identifies no human exposure data for the nominated LKKTETQ fragment and notes immunogenicity and impurity concerns. TB-500 names may refer to differing products.
This is not an exhaustive safety or contraindication list. An absence of reported harm is not proof of safety. Pregnancy, breastfeeding, cancer history, endocrine disease and concurrent medicines can materially change risk. Unregulated preparations add identity, contamination and sterility risks.
Read FDA’s compounding safety informationRegulatory status · United States
Not FDA-approved
No FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval.
Regulatory status and evidence strength are different. A nomination for compounding, a clinical-trial registration or a “research use only” label is not approval. International rules vary; consult the current regulator and product label.
Selected literature & source transparency
Matched bibliographic records confirm a publication’s identity, not the validity of every claim. Selected sources are not a systematic literature review.
Continue your own source search
These open search results, not additional verified citations. Trial registration is not evidence that a treatment works.
Three questions worth bringing to your clinician
- Which human outcomes—not just biomarkers—support this claim?
- What established options address my actual health concern?
- What do my medical history and current medicines change about the risks?
Beyond the library
Turn better questions into a thoughtful conversation.
Explore our broader health optimization approach. A library entry does not mean a molecule is offered, prescribed, or appropriate for you.
Request an Optimization Consultation
Continue to our existing activation & intake page.